

| For these study designs: | Is the specific research visit <u>"essential to the health and/or well-being"</u> of the participant, thus supporting in-person visits? | | |
|---|---|--|--|
| | These visit types are LIKELY "essential" (supports an in-person visit) | These visit types may or may not be "essential" (Support for in-person visit will depend on specifics of the study) | These visit types are LIKELY not "essential" (does not support an in-person visit) |
| Randomized controlled efficacy trial (e.g., phase IIb or III) of a potential drug or device or other intervention | Treatment Visits | <ul style="list-style-type: none"> • New enrollments if study is pre-existing and there are limited/no treatment alternatives | <ul style="list-style-type: none"> • Research or SOC blood draws • Research Only Procedures (e.g biopsy) • AE/Conmed visits • Mid cycle visits that do not include treatment • New enrollments where there is another viable treatment option |
| Post-approval trial (e.g., phase IV) of a therapeutic drug, device, or other intervention to assess tolerability and/or long-term benefit | <ul style="list-style-type: none"> • Treatment visits | | <ul style="list-style-type: none"> • New enrollments if study is pre-existing • Research or SOC blood draws • Research Only Procedures (e.g biopsy) • AE/Conmed visits • Mid cycle visits that do not include treatment • New enrollments where there is another viable treatment option |
| Early phase (e.g., phase I or IIa) pharmacodynamic, safety, tolerability or feasibility trial of a potential drug or device or other intervention | <ul style="list-style-type: none"> • Treatment visits • Investigator deemed necessary safety visits | <ul style="list-style-type: none"> • New enrollments if study is pre-existing where the patient does not have another viable treatment option | <ul style="list-style-type: none"> • Research or SOC blood draws • Research Only Procedures (e.g biopsy) • AE/Conmed visits • Mid cycle visits that do not include treatment • New enrollments where there is another viable treatment option |
| Non-randomized interventional trial of a drug, device, or other intervention requiring safety monitoring | <ul style="list-style-type: none"> • Safety Visits | <ul style="list-style-type: none"> • New enrollments if study is pre-existing | <ul style="list-style-type: none"> • Research or SOC blood draws • Research Only Procedures (e.g biopsy) • AE/Conmed visits • Mid cycle visits that do not include treatment • New enrollments where there is another viable treatment option |

| | | | |
|---|--|--|--|
| Non-randomized interventional trial of a drug, device, or other intervention not requiring safety monitoring | | <ul style="list-style-type: none"> • New enrollments if study is pre-existing • Follow ups | <ul style="list-style-type: none"> • Research or SOC blood draws • Research Only Procedures (e.g biopsy) • AE/Conmed visits • Mid cycle visits that do not include treatment • New enrollments where there is another viable treatment option |
| Comparative effectiveness studies or other study types describing the natural history of disease or other clinical outcomes | | | <ul style="list-style-type: none"> • New enrollments, follow ups |
| Non-interventional qualitative study | | | <ul style="list-style-type: none"> • New enrollments |
| Non-interventional study with collection of clinical data and/or biological specimens for future research | | | <ul style="list-style-type: none"> • New enrollments • Follow ups |